Drug Related Products
(SLXP) Salix Pharmaceuticals – Bull of the Day
Salix Pharmaceuticals (SLXP) third quarter results exceeded expectations with higher revenues boosting performance. With the company raising its revenue guidance, we have raised our estimates as well. Salix is well-positioned for growth in the gastrointestinal market. We believe...
28Nov2011 | vitalstocks | 0 comments | Continued(SLXP) Salix Pharmaceuticals – Bull of the Day
Salix Pharmaceuticals (SLXP) third quarter results exceeded expectations with higher revenues boosting performance. With the company raising its revenue guidance, we have raised our estimates as well. Salix is well-positioned for growth in the gastrointestinal market. We believe...
28Nov2011 | vitalstocks | 0 comments | Continued(PRGO) Perrigo Company – Bull of the Day
Perrigo Company (PRGO) reported earnings per share of $1.10 for the first quarter of fiscal 2012, beating the Zacks Consensus Estimate of $1.03 and the year-earlier earnings of $0.87. Perrigo upped fiscal 2012 earnings per share outlook from $4.50-$4.65 to $4.65-$4.80 due to...
17Nov2011 | vitalstocks | 0 comments | Continued(PRGO) Perrigo Beats Earnings Forecast – Sales Miss
Perrigo Company (PRGO) reported earnings per share of $1.10 for the first quarter of fiscal 2012, beating the Zacks Consensus Estimate of $1.03 and the year-earlier earnings of 87 cents per share. Light sales performance was offset by a lower tax rate to drive earnings growth. First...
2Nov2011 | vitalstocks | 0 comments | Continued(PRGO) Perrigo Downgraded to Neutral
We recently moved to a Neutral rating on Perrigo Company (PRGO) from Outperform. Our target price on the stock is $94.00. Perrigo’s broad line of store brand pharmaceutical products has the same active ingredients and comparable quality and efficacy as the national brands....
10Jul2011 | vitalstocks | 0 comments | Continued(PRGO) Perrigo Cruises Past Estimates – Lifts Outlook
Perrigo Company (PRGO) reported earnings per share of $1.07 for the third quarter of fiscal 2011, easily beating the Zacks Consensus Estimate of 96 cents and the year-earlier earnings of 81 cents per share. Results were driven by a solid top-line performance. Third quarter revenues...
8May2011 | vitalstocks | 0 comments | Continued(PRGO) Perrigo Resolves Manufacturing Issues with FDA
Perrigo Company (PRGO) recently announced the resolution of manufacturing issues at its Allegan, Michigan facility with the US Food and Drug Administration (FDA) following conclusion of re-inspection of the facility by the agency. The FDA commenced a re-inspection of the facility...
13Apr2011 | vitalstocks | 0 comments | Continued(AUXL) Auxilium Pharmaceuticals Reports Narrower Loss
Auxilium Pharmaceuticals, Inc. (AUXL) reported a third quarter loss of 27 cents per share, narrower than the Zacks Consensus Estimate of a loss of 30 cents and the year-ago loss of 35 cents. Higher revenues helped the company post a lower loss. Net revenues increased 27.3% to...
24Nov2010 | vitalstocks | 0 comments | Continued(SLXP) Salix Pharmaceuticals Posts Narrower Third Quarter 2010 Loss
Salix Pharmaceuticals, Ltd. (SLXP) posted a loss of 5 cents per share in the third quarter of 2010, narrower than the Zacks Consensus Estimate of a loss of 15 cents and the guidance provided by the company (loss of 13 cents). Salix had reported a loss of 15 cents in the year-ago...
17Nov2010 | vitalstocks | 0 comments | Continued(PRGO) Perrigo Company – Earnings Estimates Jump
Perrigo Company (PRGO) recently hit a new multi-year high at $64.66 after reporting a solid Q3 earnings surprise of 21% in late April. Estimates are on the upswing and shares are trading in line with their industry peers. Company Description Perrigo Company, through its subsidiaries,...
20May2010 | vitalstocks | 0 comments | Continued(SLXP) Salix Pharmaceuticals Exceeds Consensus Estimates
Salix Pharmaceuticals, Ltd. (SLXP) reported a net loss of 45 cents per share in the first quarter of 2010, 6 cents better than the Zacks Consensus Estimate. The company had guided towards a net loss of 50 cents. Salix reported a net loss of 29 cents in the year-ago period. Net...
17May2010 | vitalstocks | 0 comments | Continued(AUXL) Auxilium Pharmaceuticals Reports Quarterly Loss That Narrows
Strong Testim sales helped Auxilium Pharmaceuticals, Inc. (AUXL) report a narrower-than-expected net loss of 18 cents per share in the first quarter of 2010, 13 cents below the Zacks Consensus Estimate and year-ago net loss of 31 cents. Net revenues increased 31.1% to $45.5 million...
6May2010 | vitalstocks | 0 comments | Continued(HLF) Herbalife Incorporated – Earnings Estimates Up
Herbalife, Inc. (HLF) recently hit a new 52-week high above $47 after shares jumped above a short-term level of resistance on strong Q4 results from late February and a bullish next-year estimate. Fourth-Quarter Results Shares of HLF rebounded from a key trend line after the...
5Apr2010 | vitalstocks | 0 comments | Continued(SLXP) Salix Pharmaceuticals Earns FDA Approval for Xifaxan
Salix Pharmaceuticals, Ltd. (SLXP) received a huge boost recently with the US approval of Xifaxan 550 mg. The Food and Drug Administration (FDA) granted approval for the use of Xifaxan 550 mg in reducing the risk of the recurrence of overt hepatic encephalopathy (HE) in adult...
29Mar2010 | vitalstocks | 0 comments | Continued(SLXP) Salix Pharmaceuticals Beats Forecasts but Outlook Disappoints
Salix Pharmaceuticals, Ltd. (SLXP) reported a net loss of 13 cents per share in the fourth quarter, a penny better than the Zacks Consensus Estimate and company guidance of a net loss of 14 cents. Salix reported a net loss of 12 cents in the year-ago period. Higher product sales...
10Mar2010 | vitalstocks | 0 comments | Continued(HLF) Herbalife – Return on Equity of 64.8% is Far Ahead of Industry Average
Herbalife (HLF) is expected to grow its earnings per share at 13.5% for the next five years. This Zacks Rank #2 stock also pays a decent dividend. Company Description Herbalife Ltd. is a global network marketing company that sells weight-management, nutrition and personal care...
10Mar2010 | vitalstocks | 0 comments | Continued(SLXP) Salix Pharmaceuticals Focuses on Label Expansion
Salix Pharmaceuticals, Ltd. (SLXP) is slated to report fourth quarter as well as fiscal 2009 results on March 9. The current Zacks Consensus Estimate for the fourth quarter of 2009 is a loss of 14 cents. For the full year, the Zacks Consensus Estimate stands at a loss of 89 cents. Salix...
8Mar2010 | vitalstocks | 0 comments | Continued(NTY) NBTY Incorporated – Reports Record First Quarter Results
NBTY Inc. (NTY) recently surprised on estimates for the fourth quarter in a row as sales hit a first quarter record. NBTY has a forward P/E of just 11.9. Company Description NBTY manufactures and distributes nutritional supplements in the United States and around the globe. The...
3Mar2010 | vitalstocks | 0 comments | Continued(SLXP) Salix Pharmaceuticals Gets Good News From FDA
Salix Pharmaceuticals, Ltd. (SLXP) received good news recently when the Food and Drug Administration’s (FDA) Gastrointestinal Drugs Advisory Committee recommended the approval of Xifaxan (500 mg) for the maintenance of remission of hepatic encephalopathy (HE). Xifaxan is...
1Mar2010 | vitalstocks | 0 comments | Continued(AUXL) Auxilium Pharmaceuticals’ Xiaflex Awarded FDA Approval
Auxilium Pharmaceuticals, Inc. (AUXL) recently received a major boost when the U.S. Food and Drug Administration (FDA) granted approval to Xiaflex for the treatment of adult Dupuytren’s contracture patients with a palpable cord. The approval comes several months after an...
3Feb2010 | vitalstocks | 0 comments | Continued(AUXL) Auxilium Pharmaceuticals and Pfizer Announces EU Review Process
Auxilium Pharmaceuticals, Inc. (AUXL) and Pfizer Inc. (PFE) recently announced that the review process of their Marketing Authorization Application (MAA) for Xiaflex has commenced in the European Union. Pfizer was informed by the European Medicines Agency (EMEA) that the Xiaflex...
25Jan2010 | vitalstocks | 0 comments | Continued(NTY) NBTY Incorporated – Consensus Earnings Estimates Jump
NBTY Inc. (NTY) recently announced preliminary fiscal first-quarter results which showed sales jumped 14%. The company has a PEG ratio of just 0.90 and is trading at 12.6x forward earnings. Company Description NBTY manufactures and distributes nutritional supplements in the United...
15Jan2010 | vitalstocks | 0 comments | Continued(HLF) Herbalife Limited – Return on Equity of 65% Beats Industry Average of 15%
Herbalife Ltd. (HLF) has more than doubled the market’s return over the past year. Analysts polled by Zacks boosted forecasts on Herbalife’s recent reaffirmation of 2009 and 2010 earnings outlook. Company Description Herbalife Ltd. is a global network marketing company...
15Jan2010 | vitalstocks | 0 comments | Continued(SLXP) Salix Pharmaceuticals to File for IBS Indication
Salix Pharmaceuticals, Ltd. (SLXP) recently held a pre-NDA meeting with the U.S. Food and Drug Administration (FDA) related to the company’s new drug application (NDA) for rifaximin for the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS). The...
16Dec2009 | vitalstocks | 0 comments | Continued(PRGO) Perrigo Company – Revenues Spike Year-Over-Year
Perrigo Co. (PRGO) analysts are steadily increasing estimates for the drug company, fueled by the latest earnings surprise. Company Description Perrigo Co. makes OTC and generic prescription drugs, nutritional products, pharmaceutical ingredients, and other consumer products....
10Dec2009 | vitalstocks | 0 comments | Continued(HLF) Herbalife Ltd. – Analysts Polled Remain Bullish on Earnings
Herbalife Ltd. (HLF) continues to trade higher, closing in on a 52-week high and outpacing the market since the stock was last featured as a Momentum pick. During the past year, shares soared about 130% past the S&P 500. Analysts polled by Zacks remain bullish on earnings,...
7Dec2009 | vitalstocks | 0 comments | Continued(NTY) NBTY Incorporated – Reports Record Fourth Quarter Results
NBTY Inc. (NTY) just posted record results for the fiscal fourth quarter as sales jumped 12%. The company is not only a value stock but analysts expect earnings to grow at 13.75% over the next 5 years. NBTY has a PEG ratio of just 0.90. Company Description NBTY manufactures and...
14Nov2009 | vitalstocks | 0 comments | Continued(HLF) Herbalife Limited – Earnings Estimates Advance
Herbalife Ltd. (HLF) recently spiked higher after reporting better than expected third-quarter results. Company Description Herbalife Ltd. is a network marketing company that sells weight management and nutritional supplements worldwide. The company was founded in 1980 and has...
14Nov2009 | vitalstocks | 0 comments | Continued(SLXP) Salix Pharmaceuticals Beats Expectation on Xifaxan’s Strength
Salix Pharmaceuticals, Ltd. (SLXP) reported a net loss of 15 cents per share in the third quarter, which was significantly better than the Zacks Consensus Estimate of a net loss of 29 cents. The company reported a net loss of 11 cents in the year-ago period. Although revenue...
12Nov2009 | vitalstocks | 0 comments | Continued(AUXL) Auxilium Pharma Awaiting FDA Decision
Auxilium Pharma (AUXL) is currently awaiting a decision from the U.S. Food and Drug Administration (FDA) on its key pipeline candidate, Xiaflex, which is under FDA review for the treatment of Dupuytren’s Contracture. In September, Auxilium received a major boost in the form...
14Oct2009 | vitalstocks | 0 comments | Continued